Adjuvant Immunotherapy for Cancer Cachexia and Immunosuppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including chemotherapy and radiotherapy, often have limited effectiveness and are associated with significant adverse side effects, such as immunosuppression, cachexia, and resistance of tumor cells, which compromise the quality of life and treatment outcomes for patients.
Innovation Solution
A combination of drugs and treatments featuring a biological response modifier, proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride, which stimulates endogenous production of TH-1 type immune response cytokines like IFN-gamma and IL-2, enhancing the immune system's ability to combat cancer while minimizing toxicity and side effects of other treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy and radiotherapy are used to treat cancer, then tumor cells are destroyed, but immunosuppression and adverse side effects occur
Solution Approach 1:
The patent introduces adjuvant immunotherapy as an intermediary treatment that bridges conventional chemotherapy/radiotherapy and the immune system. The immunotherapy agents (cytokines, vaccines, immunomodulators) act as mediators to enhance immune response against tumor cells while protecting normal tissues from treatment-induced immunosuppression and toxicity
Solution Approach 2:
The patent employs composite treatment protocols that combine multiple therapeutic agents with different mechanisms of action. These include combinations of chemotherapy drugs with immunomodulators, cytokines with vaccines, and multiple immunotherapy agents working synergistically to achieve enhanced anti-tumor efficacy while reducing individual agent toxicity
2Reliability
If higher doses or more intensive treatment regimens are used, then treatment effectiveness increases, but toxicity increases
Solution Approach 1:
The patent utilizes parameter changes in the form of dose escalation strategies combined with immunotherapy protection. By modifying the dosage parameters of chemotherapy agents and combining them with immunoprotective agents, the treatment achieves higher effective doses against tumors while maintaining acceptable toxicity levels through immune system enhancement
Solution Approach 2:
The patent implements continuous or repeated administration of immunotherapy agents alongside conventional treatments. This continuous immunostimulatory action maintains enhanced immune surveillance and protection throughout the treatment course, allowing sustained effective dosing without cumulative toxicity
3Reliability
If conventional treatments are used, then tumor cells are targeted, but cachexia occurs
Solution Approach 1:
The patent converts the harmful cachexia-inducing effects of conventional treatments into beneficial outcomes by introducing immunotherapy agents that stimulate anti-tumor immunity. The enhanced immune response selectively targets and destroys tumor cells while preserving normal tissues, thereby preventing the catabolic state and muscle wasting characteristic of treatment-induced cachexia
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach increases the effectiveness of existing treatments, reduces immunosuppression, reverses cachexia, and improves the quality of life by inducing a potent immune response against cancer with minimal adverse effects, allowing for higher doses or more intensive regimens without increased toxicity.
Implementation Method 1
st imulates endogenous production of TH-1 type immune response cytokines like IFN-gamma and IL-2
Data Source
AI summary
The present invention comprises a new combination or association of pharmacologically active substances and/or non-drug treatments for cancer. According to the present invention, the combination or association of substances and/or non-drug treatments is used to treat cancer, clinical problems associated to cancer and adverse side effects related to substances and/or treatments used to fight this illness. The components of the combination or association of substances, the biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) and at least one substance and/or treatment with antineoplastic properties can be jointly or simultaneously or consecutively or sequentially administered in an appropriate form, according to their chemical properties, and with the use of the most suitable procedures, and also in the most therapeutically effective dose and use.